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Abstract
Introduction Mechanical ventilation has been shown to cause
lung injury and to have a significant impact on mortality in acute
respiratory distress syndrome. Theoretically, high frequency
oscillatory ventilation seems an ideal lung protective ventilation
mode. This review evaluates determinants of mortality during
use of high frequency oscillatory ventilation.
Methods PubMed was searched for literature reporting
randomized trials and cohort studies of high frequency
ventilation in adult patients with acute respiratory distress
syndrome. Data on mortality and determinants were extracted
for patients treated with high frequency oscillatory ventilation.
Linear regression analyses were conducted to produce
graphical representations of adjusted effects of determinants of
mortality.
Results Cohorts of patients treated with high frequency
oscillatory ventilation from two randomized trials and seven
observational studies were included. Data from cohorts
comparing survivors with non-survivors showed differences in
age (42.3 versus 51.2 years), prior time on conventional
mechanical ventilation (4.0 versus 6.2 days), APACHE II score
(22.4 versus 26.1), pH (7.33 versus 7.26) and oxygenation
index (26 versus 34). Each extra day on conventional ventilation
was associated with a 20% higher mortality adjusted for age
and APACHE II score (relative risk (RR) 1.20, 95% confidence
interval (CI) 1.15–1.25). However, this association was
confounded by differences in pH (pH adjusted RR 1.03, 95% CI
0.73–1.46). Oxygenation index seemed to have an independent
effect on mortality (RR 1.10, 95% CI 0.95–1.28).
Conclusion Prolonged ventilation on conventional mechanical
ventilation prior to high frequency oscillatory ventilation was not
related to mortality. Oxygenation index was a determinant of
mortality independent of other disease severity markers.
Introduction
Acute respiratory distress syndrome (ARDS) is a clinical con-
dition that is associated with high mortality [1]. Different lung
protective ventilation strategies have had an important impact
on mortality in ARDS [2]. These strategies are based on the
concept that there is a safe window between atelectasis and
overdistension of alveoli and have been developed, therefore,
with the aim of recruiting alveoli combined with avoidance of
high peak inspiratory pressures and thus overdistension. A
striking impact of how ventilation can affect outcome has been
demonstrated by comparing high tidal volume with low tidal
volume ventilation strategies, resulting in a 8.8% reduction in
mortality in the latter [3]. The most extreme form of low tidal
volume ventilation is represented by high frequency oscillatory
ventilation (HFOV). In HFOV, a continuous distending airway
pressure is applied upon which pressure waves are produced,
with frequencies typically ranging from 5 to 10 Hz. To produce
these pressure waves, a HFOV ventilator is equipped with a
piston driven diaphragm. A power control regulates the force
and distance with which the piston moves from baseline. The
degree of deflection of the piston (amplitude) determines the
tidal volume [4]. This results in extremely small tidal volumes
and, therefore, theoretically, in avoidance of overdistension; at
the same time, application of continuous distending pressure
prevents atelectasis. Thus, theoretically, these attributes make
ARDS = acute respiratory distress syndrome; CI = confidence interval; CV = conventional mechanical ventilation; FiO2 = fraction of inspired oxygen; 
HFOV = high frequency oscillatory ventilation; MAP = mean airway pressure; OI = oxygenation index; PaCO2 = pressure of arterial carbon dioxide; 
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HFOV an ideal candidate for ventilation of patients with a
severe lung disease like ARDS [5,6].
Due to technical restrictions, the first HFOV ventilators only
had the power to ventilate infants and small children. A popu-
lation in which HFOV has been extensively investigated con-
sists of premature neonates with idiopathic respiratory
distress syndrome. Although numerous randomized trials have
been performed, a clinically relevant difference in mortality or
pulmonary outcome compared with conventional mechanical
ventilation (CV) has not been established [7]. More recent
studies looked at the smallest premature infants and strived to
minimize time on CV in order to maximize the effect of HFOV
compared with CV [8,9]. Yet, it seemed that elective applica-
tion of HFOV did not influence pulmonary outcome in most
premature infants with idiopathic respiratory distress syn-
drome [10]. Attention has been shifted, therefore, to identify-
ing subgroups of patients that do benefit from HFOV.
In ARDS, only two randomized trials have been performed in
adult patients and one in pediatric patients [11-13]. None of
these trials were able to show a significant difference in mor-
tality between HFOV and CV. Studies have also been pub-
lished that investigated determinants of mortality in HFOV
treated patients [14,15]. As in studies with premature
neonates, selecting the proper subgroup of patients with
ARDS for HFOV treatment will be a main issue in trials com-
paring HFOV with CV [16]. HFOV treated patients in experi-
mental trials and in non-experimental prospective and
retrospective cohort studies were evaluated to identify base-
line characteristics that predicted mortality and pulmonary out-
come in patients who were selected for HFOV treatment.
Materials and methods
A literature search was carried out to identify all randomized
trials of HFOV performed in adult patients with ARDS. Reports
of prospective and retrospective cohort studies were sepa-
rately collected using the terms 'high frequency oscillatory
ventilation', 'acute respiratory distress syndrome' and 'mortal-
ity' in PubMed and the Cochrane database. This search was
updated until September 2005 with no further time limits. Lit-
erature lists of meta-analyses and articles were searched for
additional studies. To be included, prospective or retrospec-
tive studies had to report on well defined cohorts of patients
included over a fixed period of time and address mortality as
outcome. Case reports, case series, letters and narrative
reviews were excluded. Studies were evaluated regarding
selection bias and loss-to follow up by CB.
Data extracted for HFOV treated patients in clinical trials and
cohort studies were clinically relevant outcome measures,
mortality incidence at 30 days in survivors, incidence of still
being ventilated at 30 days, and incidence of survival without
being ventilated at 30 days. Baseline characteristics of these
cohorts that could be associated with mortality were identified.
As well as age, sex, and acute physiology and chronic health
evaluation (APACHE) II score, the following quantitative varia-
bles were extracted from all studies: ratio of partial arterial oxy-
gen pressure (PaO2; mmHg) and fraction of inspired oxygen
(FiO2); time on CV prior to HFOV (days); oxygenation index
(OI), which corresponds to FiO2 × mean airway pressure
(MAP; cmH2O) × 100)/paO2; blood gas results (pH and pres-
sure of arterial carbon dioxide (PaCO2; mmHg)); and ventila-
tory settings on CV (peak inspiratory pressure, peak end-
expiratory pressure, MAP and FiO2).
Two  a priori hypotheses were formulated to explain differ-
ences in mortality rates between studies in HFOV treated
patients: first, a longer duration on CV prior to HFOV causes
higher mortality; and second, higher baseline OI is independ-
ently associated with higher mortality in HFOV treated
patients. These hypotheses have also been raised by others to
explain differences between studies [17-19]. However, the
association of time on CV prior to HFOV and mortality in
HFOV treated patients could be confounded by covariates
such as age and disease severity (APACHE II score and pH).
In the relationship between time on CV and mortality, OI could
be an intermediate cause (Figure 1). Intermediate cause was
defined as a factor in a causal pathway; therefore, controlling
for an intermediate cause removes the association between an
explanatory variable and outcome. If controlling for a well
measured intermediate cause does not remove the associa-
tion, it is not an intermediate cause.
Statistical analysis
Univariate logistic regression analyses were performed to
identify associations between single covariates and binary out-
come (for example, survival yes or no). Mean values of reported
continuous covariates in survivors and non-survivors in each
study were used as covariates. These analyses were weighted
by numbers of survivors and non-survivors.
Figure 1
Theoretical causal mechanism of the association between time on con- ventional mechanical ventilation (CV) prior to initiating high frequency  oscillatory ventilation and mortality at 30 days Theoretical causal mechanism of the association between time on con-
ventional mechanical ventilation (CV) prior to initiating high frequency 
oscillatory ventilation and mortality at 30 days. Conditioning by oxygen-
ation index and age and APACHE II score would block the association 
if no unidentified intermediate causes or confounders were present. E, 
exposure; I, intermediate cause; C, confounders; Y, outcome.Available online http://ccforum.com/content/10/1/R34
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Linear regression analyses were conducted with mortality as
dependent outcome and determinants of mortality as inde-
pendent variables to create graphical presentations of crude
and adjusted effects. For the dependent variable, a linear
transformation of incidence of death was calculated by taking
the natural logarithm of incidence of death divided by inci-
dence of survival. The weight of an individual study was deter-
mined by the inverse of the variance of that study.
Multivariable linear regression was used to deal with possible
confounding factors of the association between hypothesized
causal factors (see Materials and methods) and outcome. Fur-
thermore, we explored in these models whether associations
between hypothesized causal factors and outcome could be
explained by possibly intermediate factors. To that end we
investigated whether inclusion in the model of such intermedi-
ate factors would indeed attenuate the association between
hypothesized causal factors and outcome, which we will refer
to as 'blocking of the effects'.
All analyses were conducted using SPSS 12.0.1 for Windows
software (SPSS Inc., Chicago, Illinois, USA).
Results
Using the search term 'high frequency oscillatory ventilation',
693 articles were found. Limiting the search to studies of
adults, only 76 articles were left. Of these 76 articles, 2 were
randomized trials and 7 observational cohort studies; 3 of
these 9 studies were retrospective studies [14,20,21] and 6
were prospective studies [11,13,15,17,18,22]. Prospective
studies contributed 83% of the total weight to our analyses.
Nine cohorts of HFOV treated patients from two randomized
trials and seven observational trials were included in the
regression analyses [11-15,17,18,20-22].
Differentiated data on survivors and non-survivors in HFOV
could be extracted from eight studies [11,13-15,17,18,20-
22]. Pooled comparison of survivors with non-survivors in the
Table 1
Comparison of survivors and non-survivors treated with high 
frequency oscillatory ventilation
Survival OR (crude)
No (60) Mean Yes (33) Mean
Age 51.2 42.3 1.14
APACHE II 26.1 22.4 1.12
TimeCV 6.2 4.0 1.38
pH 7.26 7.33 0.74a
PaCO2 54.6 43.8 1.07
PAF 91.8 94.8 0.90
OI 34.0 26.0 1.05
PIP 36.7 34.1 1.61
PEEP 14.5 13.9 1.09
MAP 24.0 22.9 1.81
FiO2 0.90 0.84 1.05a
Values are presented as pooled means of studies weighted by 
number of patients.
aOR per 0.01 unit change. FiO2 = fraction of inspired oxygen; MAP, 
mean airway pressure (cmH2O); OI, oxygenation index; OR, odds 
ratio; PaCO2, pressure of arterial carbon dioxide (mmHg); PAF, 
pressure of arterial oxygen (mmHg)/fraction of inspired oxygen; 
PEEP, peak end-expiratory pressure (cmH2O); PIP, peak inspiratory 
pressure (cmH2O); TimeCV, time on conventional mechanical 
ventilation (CV) prior to high frequency oscillatory ventilation (days).
Table 2
Linear regression analysis of determinants of mortality in high frequency oscillatory ventilation
Study Mort Vent Surv NoPat Age Sex APACHE II TimeCV pH PaCO2 PAF OI PIP PEEP MAP FiO2
[15] 0.53 17 38.0 0.5 23.3 5.0 44.7 47.8 54.3 18.3
[22] 0.20 5 36.6 2.6 28.7 6.0
[18] 0.67 0.33 24 48.4 8.3 21.5 5.7 55.1 98.9 32.5 36.7 14.5 24.3 0.78
[13] 0.37 0.43 0.36 75 48.0 0.5 22.0 2.7 7.37 44.0 114.0 24.0 39.0 13.0 22.0 0.71
[21] 0.31 16 38.0 26.6 7.0 7.30 8.4 27.4 35.1 11.6
[17] 0.43 42 49.0 0.7 28.0 3.0 7.33 57.0 94.0 23.0 35.0 15.0 24.0 1.00
[14] 0.62 0.53 0.18 154 47.9 56.6 24.0 5.7 7.28 53.2 91.2 31.4 36.1 14.0 24.1 0.86
[20] 0.32 25 42.4 4.9 97.0 26.8
[11] 0.43 0.19 0.46 37 50.7 14.3 21.1 2.1 7.30 53.5 25.2 33.1 13.9 21.5 0.84
Values are presented as pooled means of studies. FiO2, fraction of inspired oxygen; MAP, mean airway pressure (cmH2O); Mort, mortality 
incidence at 30 days; NoPat, number of patients; OI, oxygenation index; PaCO2, pressure of arterial carbon dioxide (mmHg); PAF, pressure of 
arterial oxygen (mmHg)/fraction of inspired oxygen; PEEP, peak end-expiratory pressure (cmH2O); PIP, peak inspiratory pressure (cmH2O); Surv, 
survival at 30 days without ventilation; TimeCV, time on conventional mechanical ventilation (CV) prior to high frequency oscillatory ventilation 
(days); Vent, ventilation at 30 days.Critical Care    Vol 10 No 1    Bollen et al.
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observational studies showed differences in all covariates
(Table 1). Crude odds ratios for mortality were calculated for
covariates separately. The crude odds ratio for time on CV was
1.38. However, patients that did not survive were also more
severely ill (APACHE II score 26 versus 22, pH 7.26 versus
7.33 and OI 34 versus 26).
Coverage of determinants of mortality was complete for age,
APACHE II score and OI in seven studies (Table 2). Only five
studies supplied both time on CV, pH, PaCO2 and OI. The
results from weighted multivariate linear regression analyses
of mortality incidence in HFOV treated patients are graphically
depicted in Figure 2. Adjusting for age and APACHE II score
increased the effect of prior time on CV on mortality by 23%
per day (relative risk (RR) 1.23 and 95% confidence interval
(CI) 1.01–1.49, and RR 1.35 and 95%CI 1.12–1.63 for crude
and adjusted, respectively). Addition of OI to the model with
age and APACHE II score resulted in a decreased effect of
20% increase in mortality per day on CV (RR 1.20, 95% CI
1.15–1.25).
However, the association of time on CV with mortality almost
disappeared when adjusting for pH (RR 1.03, 95% CI 0.73–
1.46). On the other hand, adjusting for PaCO2 did not diminish
the effect of time on CV (RR 1.28, 95% CI 1.20–1.36). The
association of OI with mortality was less influenced by adjust-
ing for pH (RR 1.10, 95% CI 0.95–1.28). Figures 3 and 4
show the relative contributions to mortality by days on CV prior
to HFOV and OI adjusted for different levels of baseline pH.
Data on pH could be extracted from only five studies; there-
fore, a full model with time on CV, age, APACHE II score, pH
and OI could not be fitted.
Discussion
The combined evidence from the randomized trials and obser-
vational research of cohorts of HFOV treated patients shows
that the association of prior time on CV before initiating HFOV
with mortality was confounded by differences in pH between
survivors and non-survivors. Furthermore, adjusting prior time
on CV by OI as an intermediate cause did not block the effect
of prior time on CV. OI, on the other hand, was associated with
mortality, independently of age, APACHE II score and pH.
In this review, we combined observational evidence of an addi-
tional randomized trial with a previously reported trial and pro-
spective and retrospective cohort studies. A priori, two
hypotheses that could explain the association between length
of ventilation on CV and OI, a marker of pulmonary disease
severity, with mortality in HFOV were formulated. Quantitative
data were available for two important possible confounders,
age and APACHE II score, in seven published cohorts and pH
and PaCO2 were reported for five cohorts.
Bias inherent to observational research could not be excluded.
Selective reporting was not considered to be a major problem,
however, because HFOV in adult patients was a relatively new
treatment without strong prior beliefs or expectations on the
side of the investigators. Missing patients that were treated
with HFOV in retrospective analyses was unlikely as well, as
this kind of treatment is easily recognized, also in retrospect.
Bias due to misclassification and loss to follow up were
regarded unlikely in the specific intensive care settings the
studies took place. Most determinants consisted of laboratory
measurements or ventilatory settings that were not likely to be
influenced by observer or recall bias.
Figure 3
Linear regression of time on conventional mechanical ventilation (CV)  on mortality adjusted for different levels of pH Linear regression of time on conventional mechanical ventilation (CV) 
on mortality adjusted for different levels of pH. Dashed line, crude anal-
ysis; colored lines, linear regression adjusted for pH.
Figure 2
Linear regression analysis of mortality and time on conventional  mechanical ventilation (CV) Linear regression analysis of mortality and time on conventional 
mechanical ventilation (CV). Dashed line, crude analysis; purple line, lin-
ear regression adjusted for age and APACHE II score; orange line, lin-
ear regression adjusted for oxygenation index.Available online http://ccforum.com/content/10/1/R34
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There was not enough information to assess possible con-
founding by other covariates and residual confounding could
not be excluded. Furthermore, this meta-analysis was
restricted to baseline characteristics. Sequential evolution of
determinants over time may be more powerful to predict mor-
t a l i t y .  H o w e v e r ,  A P A C H E  I I  s c o r e ,  p H  a n d  O I  h a v e  b e e n
shown to be strongly related to mortality [1]. The OI represents
a cost benefit ratio of ventilatory conditions and PaO2 yield and
is, theoretically, a more sensitive indicator of pulmonary condi-
tion than the PaO2/FiO2 ratio. The inverse relation of mean air-
way pressure and FiO2  with PaO2  would render it less
susceptible to specific ventilatory settings that were used.
Stratified results from the trial by Bollen and colleagues [11]
with baseline OI lower or equal to 20, or baseline OI above 20,
changed the effect of HFOV on mortality compared with CV.
This could indicate that the level of OI determined which
patients had the greatest benefit from HFOV.
The association of time on CV with increased mortality
adjusted for age and APACHE II score has been reported by
several other authors [13,15,17,18]. The proposed mecha-
nism would be through lung damage caused by CV. As we
have shown, this hypothesis is not supported by the evidence
in our analysis. As we have argued, if the association between
time on CV and mortality arises through damage to the lungs
caused by CV, we expect that conditioning for OI as a marker
of lung injury would explain this association by blocking the
effect; that is, by adjusting for OI as an intermediate cause, the
association of time on CV with mortality would disappear.
However, adjusting for OI did not influence the association
between time on CV and mortality. A possibility could be that
OI was not an appropriate marker of the intermediate causal
pathway and that unidentified intermediate determinants of
lung damage remained.
Moreover, the association of prolonged time on CV before ini-
tiating HFOV treatment and increased risk of death disap-
peared by adjusting for pH. It could be argued that pH was an
intermediate causal factor. However, adjustment for PaCO2
did not influence the association with time on CV and mortality,
suggesting that respiratory acidosis due to worsening pulmo-
nary function caused by prolonged CV treatment was not the
explanatory mechanism. Studies that presented time on CV as
a causal factor of worsening prognosis adjusted the effect for
APACHE score and ventilatory settings but not for pH [17,18].
Only a retrospective study by Mehta and colleagues [14] men-
tioned time on CV as a predictor of mortality independent of
age, APACHE II score and baseline pH. The strength of the
effect and whether the association was weakened by the
adjustment were not mentioned.
HFOV is a promising candidate for influencing mortality in
ARDS patients. Research has demonstrated remarkable dif-
ferences in mortality related to ventilation. These differences
could be mainly attributed to ventilation strategies. There is
now less discussion about the current optimal ventilation strat-
egies in CV and HFOV [23]. The challenge seems to be to
select the appropriate patients that benefit from HFOV com-
pared with CV [16,24]. Predicting mortality has proven to be
difficult because of the heterogeneous nature of ARDS. Yet
ventilatory strategies have shown a constant treatment effect
independent of predisposing clinical conditions [24]. In a
recent publication of a randomized trial, it was hypothesized
that the level of OI could determine which patients would
receive a relative benefit from HFOV compared with CV [11].
This might oppose a more elective approach in which patients
with ARDS are put on HFOV as quickly as possible to avoid
prolonged ventilation on CV rather than waiting until a certain
level of OI has been reached, as has been suggested [18].
However, the reviewed evidence presented in this report does
not support that early HFOV in ARDS would be more benefi-
cial, but that patients should be stratified by OI in future HFOV
trials.
Conclusion
Prolonged ventilation on CV prior to HFOV was not related to
mortality. OI was associated with mortality independently of
other disease markers and could be important for selecting
ARDS patients that could benefit from HFOV.
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